FDA approves Rinvoq for treatment of atopic Dermatitis
Jan 19, 2022
Serious side effects of Rinvoq include infections such as tuberculosis, a greater risk for death in people ages 50 years and older who have at least one cardiovascular risk factor, an increased risk for...
FDA approves first breath test for COVID-19
Apr 15, 2022
The test, which must be administered by a trained operator, demonstrates a high degree of accuracy.
NIH spending nearly $470 million on ‘long-haul COVID’ study
Sep 16, 2021
The goal is to uncover why some people have prolonged symptoms or develop new or returning symptoms after recovering from COVID-19.
Adverse effects generally mild after BNT162b2 mRNA booster in over 60s
Apr 18, 2022
Thirty percent of those aged 60 years or older receiving a booster reported at least one adverse event; few sought medical attention.
Pfizer-BioNTech COVID-19 vaccine receives full FDA approval
Aug 23, 2021
The vaccine will now be marketed as Comirnaty and is fully approved for the prevention of COVID-19 in individuals 16 years and older.
Risk for Guillain-Barré syndrome up after Ad.26.COV2.S vaccination
Apr 26, 2022
An adjusted rate ratio of 20.56 was found in a head-to-head comparison of the Johnson & Johnson vaccine and the Pfizer-BioNTech and Moderna COVID-19 vaccines.
FDA panel recommends approval of Johnson & Johnson booster shot
Oct 15, 2021
The booster shot is recommended for anyone 18 years and older, to be given at least two months after the first dose.
Mounjaro approved for blood glucose control in type 2 diabetes
May 20, 2022
The once-weekly injection is approved as an addition to diet and exercise.
AI algorithm accurately IDs two life-threatening heart conditions
Mar 14, 2022
The model can distinguish between hypertrophic cardiomyopathy and cardiac amyloidosis using ultrasound videos.
CDC signs off on Moderna, J&J boosters, backs mix ‘n’ match shots
Oct 22, 2021
The agency plans to release guidance early next week about who might benefit from choosing one booster over another.